6-Day Sell-Off Sends Perspective Therapeutics Stock Down -42%
Perspective Therapeutics (CATX) stock hit day 6 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -42% return. The company has lost about $156 Mil in value over the last 6 days, with its current market capitalization at about $214 Mil. The stock remains 9.7% below its value at the end of 2024. This compares with year-to-date returns of 14.6% for the S&P 500.
CATX provides isotope-based medical products, specializing in Cesium-131 brachytherapy seeds for treating various cancers, sold to medical facilities and physician practices.
If you seek an upside with less volatility than holding an individual stock, consider the Trefis High Quality Portfolio (HQ). HQ has outperformed its benchmark — a combination of S&P 500, Russell, and S&P midcap index — and achieved returns exceeding 91% since its inception. Risk management is key — consider what the long-term portfolio performance could be if you blended 10% commodities, 10% gold, and 2% crypto with HQ’s performance metrics.
Comparing CATX Stock Returns With The S&P 500
- META Stock: The Math Behind The Upside
- TSLA Stock: 4 Impending Events That Could Invalidate the Thesis
- Could This Fuel The Next Surge in Intel Stock
- EPAM Systems Stock: Strong Cash Flow Poised for a Re-Rating?
- Comcast Stock Shares $24 Bil Success With Investors
- 3M Stock Pays Out $24 Bil – Investors Take Note
The following table summarizes the return for CATX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CATX | S&P 500 |
|---|---|---|
| 1D | -4.3% | 0.6% |
| 6D (Current Streak) | -42.2% | 1.0% |
| 1M (21D) | -11.7% | 1.5% |
| 3M (63D) | -29.1% | 5.5% |
| YTD 2025 | -9.7% | 14.6% |
| 2024 | -20.6% | 23.3% |
| 2023 | 62.7% | 24.2% |
| 2022 | -36.3% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 42 S&P constituents with 3 days or more of consecutive gains and 35 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 8 | 27 |
| 4D | 8 | 6 |
| 5D | 17 | 1 |
| 6D | 5 | 1 |
| 7D or more | 4 | 0 |
| Total >=3 D | 42 | 35 |
Key Financials for Perspective Therapeutics (CATX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-40.9 Mil | $-66.8 Mil |
| Net Income | $-46.5 Mil | $-79.3 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-21.8 Mil | $-24.0 Mil |
| Net Income | $-18.2 Mil | $-21.5 Mil |
The losing streak CATX stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.